Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure
,
*Department of Cardiac Medicine Imperial College School of Medicine at the National Heart and Lung Institute London, UK
Wynn Division of Metabolic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute London, UK
Department of Cardiology, Martin-Luther-University Halle-Wittenberg, Germany
revised 18 October 1996; accepted 23 October 1996.
Correspondence: Francisco Leyva, MRCP, Wynn Institute, 21 Wellington Road, London NW8 9SQ. U.K.
Abstract
BACKGROUND: Elevated serum uric acid concentrations have been observed in clinical conditions associated with hypoxia. Since chronic heart failure is a state of impaired oxidative metabolism, we sought to determine whether serum uric acid concentrations correlate with measures of functional capacity and disease severity.
METHODS: Fifty nine patients with a diagnosis of chronic heart failure due to coronary heart disease (n=34) or idiopathic dilated cardiomyopathy (n=25) and 20 healthy controls underwent assessment of functional capacity. Maximal oxygen uptake (MVO2) and regression slope relating to minute ventilation to carbon dioxide output (VE-VCO2) were measured during a maximal treadmill exercise test. Metabolic assessment consisted of measuring serum uric acid and fasting lipids, and insulin sensitivity, obtained by minimal modelling analysis of glucose and insulin responses during an intravenous glucose tolerance test. Clustering of indices of functional disease capacity and metabolic factors was explored using factor analysis and multivariate regression analysis.
RESULTS: Compared to 20 healthy controls, patients with chronic heart failure had a 52% lower MVO2 (P<0·001), 56·8% higher serum uric acid concentrations (P<0·001) as well as a 60·5% lower insulin sensitivity (P<0·001). Salient univariate correlations in the chronic heart failure group included serum uric acid concentrations with exercise time during the exercise test (r= – 0·53), MVO2 (r= – 0·50) (both P<0·001), VE-VCO2 slope (r=0·45), and NYHA functional class (r=0·36) (both P<0·01). In factor analysis of the chronic heart failure group, serum uric acid formed part of a principal cluster of metabolic variables which included MVO2 and VE-VCO2, slope. In multivariate regression analysis, serum uric acid concentrations emerged as a significant predictor of MVO2, exercise time (both P<0·001,) VE-VCO2 slope and NYHA functional class (both P<0·02), independent of diuretic dose, age, body mass index, serum creatinine, alcohol intake, plasma insulin levels, and insulin sensitivity index.
CONCLUSIONS: There is an inverse relationship between serum uric acid concentrations and measures of functional capacity in patients with cardiac failure. The strong correlation between serum uric acid and MVO2 suggests that in chronic heart failure, serum uric acid concentrations reflect an impairment of oxidative metabolism.
Key Words: Uric acid • congestive cardiac failure • hypoxia • insulin resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W.H. W. Tang The ongoing search for a stratified medicine approach in heart failure. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2310 - 2312. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Baker, H. R. Schumacher, and E. Krishnan Serum Uric Acid Level and Risk for Peripheral Arterial Disease: Analysis of Data From the Multiple Risk Factor Intervention Trial Angiology, September 1, 2007; 58(4): 450 - 457. [Abstract] [PDF]
|
|
|
|
 |
|
 H J E M Janssens, E H van de Lisdonk, M Janssen, H J M van den Hoogen, and A L M Verbeek Gout, not induced by diuretics? A case-control study from primary care Ann Rheum Dis, August 1, 2006; 65(8): 1080 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Duncan, R. Ravi, L. B. Stull, and A. M. Murphy Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1512 - H1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Kittleson and J. M. Hare Xanthine oxidase inhibitors: an emerging class of drugs for heart failure Eur. Heart J., August 1, 2005; 26(15): 1458 - 1460. [Full Text] [PDF]
|
|
|
|
 |
|
 W Doehner and S D Anker Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart, June 1, 2005; 91(6): 707 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sanchez-Moreno, M P. Cano, B. de Ancos, L. Plaza, B. Olmedilla, F. Granado, and A. Martin Effect of orange juice intake on vitamin C concentrations and biomarkers of antioxidant status in humans Am. J. Clinical Nutrition, September 1, 2003; 78(3): 454 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Janssens, E. van de Lisdonk, H Bor, H. van den Hoogen, and M Janssen Gout, just a nasty event or a cardiovascular signal? A study from primary care Fam. Pract., August 1, 2003; 20(4): 413 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sanchez-Moreno, M. P. Cano, B. de Ancos, L. Plaza, B. Olmedilla, F. Granado, and A. Martin High-Pressurized Orange Juice Consumption Affects Plasma Vitamin C, Antioxidative Status and Inflammatory Markers in Healthy Humans J. Nutr., July 1, 2003; 133(7): 2204 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Anker, W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C. H. Davos, M. Cicoira, W. Shamim, M. Kemp, et al. Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging Circulation, April 22, 2003; 107(15): 1991 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser, S. Spiekermann, S. Dikalov, H. Tatge, R. Wilke, C. Kohler, D. G. Harrison, B. Hornig, and H. Drexler Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure: Role of Xanthine-Oxidase and Extracellular Superoxide Dismutase Circulation, December 10, 2002; 106(24): 3073 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Doehner, N. Schoene, M. Rauchhaus, F. Leyva-Leon, D. V. Pavitt, D. A. Reaveley, G. Schuler, A. J.S. Coats, S. D. Anker, and R. Hambrecht Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies Circulation, June 4, 2002; 105(22): 2619 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Sharma and S.D Anker From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D12 - D17. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Maxwell and K. A. Bruinsma Uric acid is closely linked to vascular nitric oxide activity: Evidence for mechanism of association with cardiovascular disease J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1850 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Cappola, D. A. Kass, G. S. Nelson, R. D. Berger, G. O. Rosas, Z. A. Kobeissi, E. Marban, and J. M. Hare Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy Circulation, November 13, 2001; 104(20): 2407 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.G Williams, G.A Cooke, D.J Wright, W.J Parsons, R.L Riley, P Marshall, and L-B Tan Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure Eur. Heart J., August 2, 2001; 22(16): 1496 - 1503. [Abstract] [PDF]
|
|
|
|
|
|
G. Akner and T. Cederholm Treatment of protein-energy malnutrition in chronic nonmalignant disorders Am. J. Clinical Nutrition, July 1, 2001; 74(1): 6 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ukai, C.-P. Cheng, H. Tachibana, A. Igawa, Z.-S. Zhang, H.-J. Cheng, and W. C. Little Allopurinol Enhances the Contractile Response to Dobutamine and Exercise in Dogs With Pacing-Induced Heart Failure Circulation, February 6, 2001; 103(5): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Oya, N Nagaya, T Satoh, F Sakamaki, S Kyotani, M Fujita, N Nakanishi, and K Miyatake Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome Heart, July 1, 2000; 84(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Johnson, K. R. Tuttle, B. Culleton, and D. Levy Much Ado About Nothing, or Much to Do About Something? The Continuing Controversy Over the Role of Uric Acid in Cardiovascular Disease Hypertension, March 1, 2000; 35 (3): e10 - e10. [Full Text]
|
|
|
|
 |
|
 M. A. Voelkel, K. M. Wynne, D. B. Badesch, B. M. Groves, and N. F. Voelkel Hyperuricemia in Severe Pulmonary Hypertension* Chest, January 1, 2000; 117(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mancini, A. Benaminovitz, M. E. Cordisco, W. Karmally, and A. Weinberg Slowed glycogen utilization enhances exercise endurance in patients with heart failure J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1807 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. NAGAYA, M. UEMATSU, T. SATOH, S. KYOTANI, F. SAKAMAKI, N. NAKANISHI, M. YAMAGISHI, T. KUNIEDA, and K. MIYATAKE Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 487 - 492. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. F. Culleton, M. G. Larson, W. B. Kannel, and D. Levy Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study Ann Intern Med, July 6, 1999; 131(1): 7 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Anker and A. J. S. Coats Cardiac Cachexia: A Syndrome With Impaired Survival and Immune and Neuroendocrine Activation Chest, March 1, 1999; 115(3): 836 - 847. [Abstract] [Full Text] [PDF]
|
|